MUNICH, Germany – Results of the Low-Risk TAVR (LRT) trial presented today at the European Society of Cardiology Congress 2018 showed zero all-cause mortality and zero disabling stroke at 30 days in 200 patients with low surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR).